A Novel Acylaminoimidazole Derivative, WN1316, Alleviates Disease Progression via Suppression of Glial Inflammation in ALS Mouse Model

• Kazunori Tanaka ,

  Contributed equally to this work with: Kazunori Tanaka, Takuya Kanno

  Affiliation NGP Biomedical Research Institute, Neugen Pharma Inc., Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan

  ⨯
• Takuya Kanno ,

  Contributed equally to this work with: Kazunori Tanaka, Takuya Kanno

  Affiliation NGP Biomedical Research Institute, Neugen Pharma Inc., Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan

  ⨯
• Yoshiko Yanagisawa,

  Affiliation NGP Biomedical Research Institute, Neugen Pharma Inc., Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan

  ⨯
• Kaori Yasutake,

  Affiliation NGP Biomedical Research Institute, Neugen Pharma Inc., Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan

  ⨯
• Satoshi Inoue,

  Affiliation Wakunaga Pharmaceutical Co. Ltd., Akitakada, Hiroshima, Japan

  ⨯
• Noriaki Hirayama,

  Affiliation Department of Molecular Life Sciences, Tokai University School of Medicine, Isehara, Kanagawa, Japan

  ⨯
• Joh-E Ikeda

  * E-mail: alspd@med.kitasato-u.ac.jp

  Affiliations NGP Biomedical Research Institute, Neugen Pharma Inc., Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, Department of Molecular Life Sciences, Tokai University School of Medicine, Isehara, Kanagawa, Japan, Department of Molecular Neurology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, Apoptosis Research Centre, Children’s Hospital of Eastern Ontario, Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada

  ⨯